WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

Chinesische Regierung startet F&E-Unterstützung für heimische pharmazeutische Biotechnologie... Aktienkurse steigen, einschließlich Wuxi Bio (02269) http://www.infostockdaily.co.kr/news/articleView.html?idxno=165798 ... Der Anstieg der Aktienkurse chinesischer Pharma- und Biounternehmen wird als Ergebnis des „14.5 Pharmaceutical Industry Development Plan“ der chinesischen Regierung interpretiert. Der Plan, der von neun Sektoren, darunter dem Ministerium für öffentliche Information und Sicherheit, angekündigt wurde, enthält den Inhalt, die durchschnittliche jährliche Wachstumsrate der F&E-Ausgaben in der pharmazeutischen Industrie zu erhöhen und den Umsatzanteil innovativer neuer Medikamente bis 2025 zu erhöhen. ...

Allgemein zu China-Invests, aber kurz auch zu WuXi: Comgest-Fondsmanager Chen: China-Anleger sollten sich nicht vor dem Jahr des Tigers fürchten https://e-fundresearch.com/newscenter/167-comgest/artikel/43305-comgest-fondsmanager-chen-china-anleger-sollten-sich-nicht-vor-dem-jahr-des-tigers-fuerchten

http://www.aastocks.com/en/stocks/news/aafn-con/now.1156702/latest-news

Morgan Stanley: Aktuelles Anlagerating und Kursziel von Pharmaaktien (Tabelle) Innovent Biologics (09996) und WuXi Biologics (02269) werden bevorzugt https://hk.investing.com/news/stock-market-news/article-210465

Guo Jiayao: Hong Kong stocks are expected to develop individually in the short term; WuXi Biologics (02269 HK) is looking forward to valuation repair http://www.aastocks.com/tc/stocks/news/aafn-con/.hk.220118_091816/latest-news ...WuXi Biologics  A business briefing event was held recently to provide investors with the latest business trends. The company expects ...

WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility https://www.prnewswire.com/news-releases/wuxi-biologics-completes-gmp-inspection-by-south-koreas-ministry-of-food-and-drug-safety-for-drug-substance-facility-301462389.html • WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements.

https://m.jrj.com.cn/madapter/hk/2021/12/31085634090855.shtml ...So far this year (since the passing of the ordinary resolution), the cumulative number of securities repurchased is 32.155 million shares, accounting for 0.76% of the number of shares issued at the time of passing the ordinary resolution.

Guten Rutsch 🍾🍀🙋🏼‍♀️

...und heute erneut: WuXi Biologics (02269) repurchased 4.489 million shares for HK$400 million on December 30 https://m.jrj.com.cn/madapter/hk/2021/12/30212734088520.shtml

Und es ging weiter damit: http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1152327/company-news WUXI BIO (02269 HK) Buys back 3.448M Shrs for $300M

Aktienrückkäufe sind immer gut😉 nur leider im Kurs nicht zu sehen.

WUXI BIO Splashes Almost $200M to Buy back 2.252M Shrs http://aastocks.com/en/stocks/analysis/stock-aafn-con/02269/NOW.1152150/all

aktuell WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody https://www.prnewswire.com/news-releases/wuxi-biologics-and-immuneoncia-sign-mou-for-development-and-manufacturing-of-anti-pd-l1cd47-bispecific-antibody-301450916.html ...and ImmuneOncia Therapeutics, Inc., a clinical-stage, immuno-oncology company in South Korea, today announced that a Memorandum of Understanding (MOU) was signed to form a strategic partnership in the development and manufacturing of IOH-001, ImmuneOncia's therapeutic bispecific antibody targeting PD-L1 and CD47.   ...

vom 24.12. First Shanghai: Maintain WuXi Biologics (02269) "Buy" rating target price of 108.7 Hong Kong dollars https://m.jrj.com.cn/madapter/hk/2021/12/24103534056842.shtml

Hong Kong stocks move | WuXi AppTec (02359) fell 8%, leading the decline in CXO sector demand side concerns as one of the main reasons for the sell-off https://m.jrj.com.cn/madapter/hk/2021/12/20150934034504.shtml

https://finance.yahoo.com/news/sell-rumor-fails-china-biotech-061006902.html Sell the Rumor Fails in China Biotech Stocks as They Roar Back